Clinical Trial Update: Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants. [Phase 4]

View source ↗

Summary

A Phase 4 immunogenicity and safety study of the Pneumococcal 7-valent conjugate vaccine in infants with sickle cell disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections
• Sickle Cell Disease

Drugs mentioned

• Prevnar 7 (Pneumococcal conjugate vaccine, 7-valent)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Pneumococcal Infections | Phase 4 | Status: TERMINATED